Different engines, same goal: Both funds pursue high current income through options strategies, but IWMY writes credit call spreads on the broad Russell 2000 small-cap index, while YMAX is a fund-of-funds holding single-stock covered-call ETFs. Exposure breadth: IWMY offers diversified small-cap equity exposure across many sectors; YMAX is heavily concentrated in technology and growth names.
Both ITWO and IWMW are Russell 2000 small-cap covered-call (buy-write) funds, but ITWO sells call options daily while IWMW writes them monthly, producing meaningfully different income and upside-capture profiles. ITWO carries a 0.55% expense ratio and relies on swaps to replicate its strategy, whereas IWMW charges 0.40% and physically holds the iShares Russell 2000 ETF.
JEPI is a large, actively managed equity premium income fund with roughly 135 holdings, while KHPI is a younger, concentrated hedged income strategy built almost entirely around a single S&P 500 ETF position. JEPI charges a 0.35% expense ratio versus KHPI 's 0.98%, giving JEPI a meaningful cost advantage over the long term.
IQQQ tracks the Nasdaq-100 Daily Covered Call Index, concentrating roughly 57% of exposure in technology; SPYI combines S&P 500 constituents with an actively managed call-option overlay across about 500 stocks. Both funds pursue high monthly income through option-writing mechanics, but SPYI's broader, more balanced sector mix carries less single-sector concentration risk than IQQQ's tech-heavy Nasdaq-100 focus.
Macro-driven instrument: SDS seeks daily results equal to two times the inverse (-2x) of the S&P 500 Index, making its trajectory closely tied to Federal Reserve policy, inflation, and U.S. economic growth expectations. Valuation and concentration risks: A market-cap-weighted index heavily influenced by a handful of mega-cap technology names means any earnings or sentiment setback in that cluster could support inverse exposure, while continued strength would pressure it.
Macro driver: QJN's future trajectory is tied directly to the price performance of the Nasdaq-100, meaning interest-rate expectations, inflation, and large-cap technology earnings are the dominant macro levers ahead. Defined-outcome structure: The fund caps upside near 21.90% (before fees) for the June 2026–May 2027 outcome period while buffering the first 10% of losses, shaping a narrower, more predictable return profile than a plain Nasdaq-100 holding.
Macro drivers: The direction of interest rates and Treasury yields is the single most important macro variable for this income-oriented, value-tilted portfolio, shaping both dividend-stock relative performance and covered-call premium income. Sector outlook: Heavy overweights in healthcare, financials, consumer staples, and energy versus the broad market position the fund as a defensive, value-leaning strategy that could fare differently from growth-led indexes.
Single-stock leverage concentrates risk: NVOX seeks two times (200%) the daily return of Novo Nordisk's American Depositary Receipt (ADR), so its future outlook is tied almost entirely to one pharmaceutical company. Semaglutide patent cliff is the defining issue: Loss of exclusivity (LOE) for Novo's core molecule begins in the early 2030s in major markets, pressuring the growth trajectory that underpins its valuation.
Single-stock concentration risk: DJTU seeks 200% daily exposure to the common stock of Trump Media & Technology Group Corp. ( DJT ), meaning its entire future trajectory hinges on one company rather than a diversified basket. Leverage and volatility decay are structural: Because returns reset daily, choppy or sideways trading in the underlying stock can erode value over time even when the stock's long-term direction is favorable.
Leveraged tech exposure: QQQP seeks 200% of the calendar-quarter return of the Invesco QQQ Trust ( QQQ ), amplifying both upside and downside across the Nasdaq-100's largest non-financial companies. AI and mega-cap concentration: The underlying index's performance is heavily shaped by its largest holdings, including NVIDIA, Microsoft, and Apple, tying QQQP's trajectory closely to artificial-intelligence spending and Big Tech earnings momentum.
Macro-driven leverage: BITX aims to deliver roughly twice the daily return of the S&P CME Bitcoin Futures Daily Roll Index, making it highly sensitive to Federal Reserve interest-rate policy, inflation, and liquidity conditions. Bitcoin exposure without direct coin ownership: The fund holds cash-settled CME bitcoin futures and Treasury-bill collateral rather than spot bitcoin, so futures roll costs can shape returns independently of the underlying asset's price.
Leveraged tech exposure: ROM seeks daily investment results that correspond to two times (2x) the daily performance of the S&P Technology Select Sector Index, amplifying both gains and losses. AI and semiconductor dominance: With heavy concentration in chipmakers and software leaders, the fund's future outlook hinges on sustained artificial intelligence (AI) capital spending and cloud demand.
Annual reset is the central catalyst: PMMR re-establishes its upside cap and 100% downside buffer each March, so the cap level set at the next reset will largely define return potential for the coming outcome period. Option-market pricing matters: Because the fund uses FLEX options (customizable exchange-traded options), the cap is sensitive to implied volatility and interest rates, which shift with the macro environment.
The $30 objective reflects the fund's disclosed 21.90% upside cap, which approximates the ceiling of what QJN is designed to return for the June 2026–May 2027 outcome period; it is not an analyst price target. Because QJN is a defined-outcome ETF, no credible aggregate of analyst price targets exists; the target is drawn from the issuer's published cap and buffer structure.
The central target of $66 is not an analyst consensus. As a leveraged inverse exchange-traded fund, SDS — the ProShares UltraShort S&P500 ETF — does not receive analyst price targets, so the figure is a technical, mean-reversion objective derived from public discussion and the fund's trailing trading range. The fund was recently trading near $59.50, meaning reaching $66 would require a gain of roughly 11%, a substantial move for a product that resets its exposure daily.
NVOX is a 2X daily leveraged ETF tied to Novo Nordisk, not a common stock, so no individual analyst price targets exist for the fund itself. The $15 central target is a round-number technical recovery milestone drawn from public market discussion, not an analyst consensus or average price target.
The central target discussed here is $3.00 , roughly 33% above the fund's recent price near $2.25. This target is drawn from public quantitative-model discussion (a modeled three-month scenario range and naive forecast), not from a sell-side analyst consensus, because no analysts publish price targets for DJTU.
The $245 central target reflects QQQP 's 52-week high — a clearly identifiable technical resistance milestone, not an analyst consensus, because leveraged ETFs rarely carry analyst price targets. QQQP recently traded near $181, so reaching $245 requires roughly 35% upside — a substantial move.
The $15 target is a fallback objective drawn from public market commentary and technical levels, not an analyst consensus; as a leveraged crypto ETF, BITX has no analyst price targets. With the fund recently trading near $10.50, reaching $15 would require a roughly 42% advance — a very large move even for this highly volatile vehicle.
The central target examined is $130 , established through public discussion of technical milestones rather than analyst price targets, since ROM is a leveraged ETF. ROM traded near $108–$109 in mid-November 2026, so reaching $130 would require a rise of roughly 19% , a substantial move.